HealthMore in Health →
GSK Acquires Pulmonary Hypertension Biotech 35Pharma for $950 Million
Pharmaceutical giant GSK has agreed to buy 35Pharma, a biotech focused on pulmonary hypertension, for $950 million. The deal expands GSK's respiratory and cardiovascular portfolio with a pipeline targeting a disease that currently has limited treatment options.
Key Takeaways
- GSK to acquire 35Pharma for $950M in cash, closing expected Q2 2026
- 35Pharma's lead pulmonary hypertension candidate is in late-stage clinical trials
DE
DT Editorial AI··5 min read·via endpoints.news